双支气管扩张剂治疗及三联治疗对慢性阻塞性肺疾病的疗效分析

Therapeutic Effect of Double Bronchodilator Therapy and Triple Therapy on Chronic Obstructive Pulmonary Disease

摘要: 慢性阻塞性肺疾病(COPD)即慢阻肺顾名思义是一种慢性炎症性肺病，其特征是慢性气流受限和持续的呼吸道症状(如呼吸困难、咳嗽和咳痰)。有关资料表明，40岁以上中老人群的患病率逐渐上升，但COPD具有早期难以发现、诊断困难、诊疗时间长的特征，若患者未及时诊治，其病情迅速恶化，进而引发自发性气胸、心脑血管疾病、代谢综合征等并发症。对于稳定期COPD患者而言，临床上以减轻症状和防止急性加重为治疗目的。COPD稳定期常见的药物治疗包括长效β2受体激动剂(LABA)、长效抗胆碱能药物(LAMA)、茶碱类药物、吸入糖皮质激素(ICS)等，目前对于中重度COPD患者，LAMA、LABA、ICS联治疗逐渐广泛运用于临床，且备受关注，但COPD三联治疗需进一步研究。本文对COPD三联治疗进行综述。

Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by chronic airflow limitation and persistent respiratory symptoms (such as dyspnea, cough and sputum production). Relevant data show that the prevalence of middle-aged and elderly people over the age of 40 is gradually increasing, but COPD is characterized by difficulty in early detection, difficulty in diagnosis, and long time for diagnosis and treatment. Complications such as cardiovas-cular and cerebrovascular diseases and metabolic syndrome. For patients with stable COPD, the clinical goal is to relieve symptoms and prevent acute exacerbations. Common drug treatments for stable COPD include long-acting β2-agonists (LABAs), long- acting anticholinergics (LAMAs), theo-phyllines, and inhaled glucocorticoids (ICS). LAMA, LABA, ICS combination therapy is gradually widely used in clinical practice, and has attracted much attention, but COPD triple therapy needs further research. This article reviews the triple therapy of COPD.